• Phase 3 multi-centre placebo-controlled randomized controlled trial (RCT)
• Age 40 years or older
• Patients must have at least one high-risk factor i.e. uncontrolled hypertension, HF, coronary artery disease (CAD), diabetes, obesity, etc.
• Colchicine vs. placebo
• 30-day treatment
•  N = 6000
• Primary composite endpoint of need for hospitalization or death